Patents Assigned to Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fur Gesundheit und Umwelt GmbH
-
Patent number: 10421749Abstract: The present invention relates to compounds and compositions for use in methods of treating and/or preventing conditions, disorders or diseases that are mediated or caused by a virus.Type: GrantFiled: April 7, 2016Date of Patent: September 24, 2019Assignees: HELMHOLTZ ZENTRUM MÜNCHEN-DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH), LEIBNIZINSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E. V. -HANS-KNÖLL-INSTITUTInventors: Ruth Brack-Werner, Markus Helfer, Manfred Rösner, Martha Schneider, Ulrike Protzer, Christian Hertweck, Martina Werneburg
-
Patent number: 10412927Abstract: The present invention concerns a device for improved hygienic monitoring of individually ventilated caging (IVC) rack systems for laboratory animals and method for contamination-free removal of biological samples from unwanted organisms from the IVC-rack system. The device allows the performance of sampling operations on a ventilated shelving system in a safe and effective manner, without interfering with the ventilation air flow. The method of the invention allows the removal and transfer of the biological sample from inside the IVC-rack in a contamination-free manner by enabling a safe transfer of the sample from inside the IVC-rack system to any further processing procedure for analysis of the biological sample outside the IVC-rack system. It is also an object of the present invention to provide a device which is adapted to be used also on existing ventilated shelving systems, allowing the refitting of existing IVC-rack systems.Type: GrantFiled: October 28, 2016Date of Patent: September 17, 2019Assignees: TECNIPLAST S.P.A., HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventors: Markus Brielmeier, Wolfgang Nagel, Julia Zorn, Alfredo Campiotti, II, Gianpaolo Milite, Carmelo Di Martino
-
Publication number: 20190211025Abstract: The invention relates to compounds which are suitable for the treatment of cancer, an immune disease, Parkinson's disease, Cardiac Hypertrophy or Type-2 diabetes and to pharmaceutical compositions containing such compounds. The invention further relates to a kit of parts comprising such compounds.Type: ApplicationFiled: September 18, 2017Publication date: July 11, 2019Applicant: HELMHOLTZ ZENTRUM MUENCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventors: Kamyar Hadian, Jara Kerstin Brenke, Oliver Plettenburg, Gerrit Juerjens
-
Patent number: 10314490Abstract: An imaging device includes (a) a light source device arranged to illuminate a sample under investigation with illumination light, (b) a detector device arranged to collect a plurality of images including at least one sample light image backscattered by the sample, and at least one marker light image originating from at least one marker substance in the sample, and (c) a processor device adapted to process the at least one sample light image.Type: GrantFiled: February 8, 2018Date of Patent: June 11, 2019Assignee: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Vasilis Ntziachristos, George Themelis
-
Patent number: 10292593Abstract: An imaging device configured for optoacoustic imaging of an object, including an illumination device including optical components arranged to illuminate the object, a detector device comprising an array of detector elements arranged in a tank and arranged to detect acoustic signals created in the object, and a container device including a tank arranged to accommodate the detector device, the object and a matching transmission medium, a holding device adapted to position and move the object relative to the illumination device and the detector device, wherein the optical components are arranged in the tank to illuminate the object from different directions.Type: GrantFiled: July 23, 2010Date of Patent: May 21, 2019Assignee: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Daniel Razansky, Vasilis Ntziachristos
-
Publication number: 20190000949Abstract: The present invention contemplates dendritic cell compositions. The dentritic cell compositions employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC II presentation of the antigen or fragment thereof. In particular, the invention refers to a dendritic cell vaccine comprising dendritic cells expressing a MHC class-II targeting signal fused to an antigen or fragment thereof. Dendritic cell vaccines for the stimulation of an immune response against melanoma-associated antigen are also described.Type: ApplicationFiled: December 22, 2016Publication date: January 3, 2019Applicants: MEDIGENE IMMUNOTHERAPIES GMBH, HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventors: Slavoljub MILOSEVIC, Christian ELLINGER, Carina WEHNER, Dolores SCHENDEL
-
Publication number: 20190002515Abstract: The present invention contemplates methods for the generation of human antigen-specific T lymphocytes. The methods employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC class presentation of RNA coded proteins. Accordingly, the present invention concerns expression vectors comprising MHC class-II targeting signal and at least one antigen or fragment thereof and its use for the in vitro generation of antigen-specific T lymphocytes. T cell clones and T cell receptors (TCRs) specific for tumor antigens or viral antigens are also described.Type: ApplicationFiled: December 22, 2016Publication date: January 3, 2019Applicants: MEDIGENE IMMUNOTHERAPIES GMBH, HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventors: Slavoljub MILOSEVIC, Christian ELLINGER, Carina WEHNER, Dolores SCHENDEL
-
Publication number: 20180237802Abstract: The present invention relates to a nucleic acid molecule encoding (I) a polypeptide having the activity of an endonuclease, which is (a) a nucleic acid molecule encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 2; (c) a nucleic acid molecule encoding an endonuclease, the amino acid sequence of which is at least 70% identical to the amino acid sequence of SEQ ID NO: 1; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 50% identical to the nucleotide sequence of SEQ ID NO: 2; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (e) wherein T is replaced by U; (II) a fragment of the polypeptide of (I) having the activity of an endonuclease.Type: ApplicationFiled: April 23, 2018Publication date: August 23, 2018Applicant: Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventor: Ralf KÜHN
-
Patent number: 9918640Abstract: An imaging device for medical imaging includes a light source device arranged to illuminate a sample under investigation with illumination light, a detector device arranged to collect a plurality of images including at least two sample light images backscattered by the sample in different spectral ranges, and at least one marker light image originating from at least one marker substance in the sample, and a processor device adapted to process the at least two sample light images and create at least one correction component, the processor device further adapted to correct the marker light image using the at least one correction component.Type: GrantFiled: November 15, 2010Date of Patent: March 20, 2018Assignee: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbHInventors: Vasilis Ntziachristos, George Themelis
-
Publication number: 20170153224Abstract: The present invention relates to the use of the biomarker Flattop (Fltp) for distinguishing mature ? cells from immature progenitor ? cells. The present invention further relates to a method for distinguishing a mature ? cell from an immature progenitor ? cell, the method comprising: determining the presence or absence of the biomarker Flattop (Fltp) in a ? cell; wherein the presence of Fltp in the cell indicates that the cell is a mature ? cell and wherein the absence of Fltp in the cell indicates that the cell is an immature progenitor ? cell. Furthermore, the present invention relates to a method of identifying a compound suitable for differentiating immature progenitor ? cells into mature ? cells as well as to a method of identifying a compound suitable for preventing the de-differentiating of mature ? cells.Type: ApplicationFiled: March 26, 2015Publication date: June 1, 2017Applicant: Helmholtz Zentrum München - Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GmbH)Inventors: Heiko Lickert, Adriana Migliorini, Moritz Gegg, Erik Bader
-
Patent number: 9597384Abstract: The present invention relates to semi-allogeneic antigen-presenting cells into which proteins and/or peptides or RNA or DNA or cDNA, respectively, encoding said proteins and/or peptides which are overexpressed in tumor cells or which are derived from autologous tumor cells or different tumor cells or different tumor cell lines have been introduced. Furthermore the invention relates to methods for the generation of these semi-allogeneic antigen-presenting cells as well as to the use thereof in the treatment of tumor diseases.Type: GrantFiled: December 21, 2015Date of Patent: March 21, 2017Assignee: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Dolores Schendel, Rudolf Wank
-
Publication number: 20160340412Abstract: The present invention relates to a method of producing a modified protein having an increased stability and/or improved folding efficiency as compared to the unmodified protein, the method comprising (i) modifying a nucleic acid molecule encoding a protein comprising at least one immunoglobulin constant domain-like region by (a-i) replacing the nucleotides encoding at least one amino acid, preferably an uncharged amino acid, in the loop separating the C strand from the D strand with nucleotides encoding a charged amino acid selected from the group consisting of Arg, Lys, His, Glu and Asp and/or replacing the nucleotides encoding at least one amino acid, preferably an uncharged amino acid, in the helix connecting the E strand with the F strand with nucleotides encoding a charged amino acid selected from the group consisting of Arg, Lys, His, Glu and Asp; (a-ii) replacing the nucleotides encoding at least one amino acid not having a side chain that can form a hydrogen bond in the loop separating the C strand frType: ApplicationFiled: January 7, 2015Publication date: November 24, 2016Applicants: Technische Universität München, Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Johannes Buchner, Matthias Feige, Moritz Marcinowski, Janosch Hennig
-
Patent number: 9409969Abstract: The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. The invention is further directed to a kit-of-parts or composition containing at least three groups of transgenic lymphocytes transformed with vectors coding for TCR against said antigens. Furthermore, the present invention provides a pharmaceutical composition and its use in the treatment of diseases involving malignant cells expressing said tumor-associated antigens. The invention further relates to a nucleic acid molecule coding for a TCR that recognizes the survivin antigen, a TCR encoded thereby and a T cell expressing said TCR. Further, the invention discloses a vector, a cell and a pharmaceutical composition encoding/containing same and their use in the treatment of diseases involving malignant cells expressing survivin.Type: GrantFiled: February 9, 2010Date of Patent: August 9, 2016Assignees: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZINInventors: Dolores J. Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
-
Patent number: 9341617Abstract: The present invention is directed to a method of identifying CD4+ T cell antigens as well as to antigens which were identified by such a method. The present invention further is directed to the application of those identified antigens in medicine.Type: GrantFiled: April 24, 2006Date of Patent: May 17, 2016Assignee: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Josef Mautner, Uta Behrends, Slavoljub Milosevic
-
Patent number: 9063338Abstract: An autostereoscopic display includes a background illumination with a multiplicity of parallel light strip groups with in each case at least two parallel light strips, wherein the individual light strip groups are arranged next to one another with a first grid dimension, and a lens grid arranged before the background illumination and has a multiplicity of parallel lens strips, wherein the lens strips are arranged next to one another with a second grid dimension, as well as a light modulator arranged before the lens grid and displays image information.Type: GrantFiled: March 9, 2010Date of Patent: June 23, 2015Assignee: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Christoph Hoeschen, Oleg Tischenko, Matthias Klaften, Lars Kroker, Michael Scholles, Jens Knobbe
-
Publication number: 20140141026Abstract: The present invention is directed to a method of generating antigen specific T cells. Furthermore, the invention is directed to antigen specific T cells, isolated transgenic TCR's, pharmaceutical compositions containing same and their use in adoptive cell therapy. This invention in particular pertains to the use of cells co-expressing allogeneic MHC molecules and antigens to induce peptide-specific T cells from non-selected allogeneic T cell repertoires.Type: ApplicationFiled: July 12, 2013Publication date: May 22, 2014Applicant: Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuR Gesundheit und Umwelt GmbHInventors: Dolores Jean Schendel, Susanne Wilde, Thomas Blankenstein
-
Publication number: 20140114187Abstract: An ultrasound detector adapted for ultrasound detection with medical applications includes an optical waveguide, and at least one Bragg grating, created with a predetermined refractive index modulation amplitude in the optical waveguide, wherein the at least one Bragg grating includes a localized defect in periodicity so that a localized-light resonance portion is formed around the defect, and the localized-light resonance portion has spectral properties capable of being modulated in response to an ultrasound oscillation, wherein the optical waveguide is a non-amplifying optical medium, and the refractive index modulation amplitude is selected such that the localized-light resonance portion is concentrated at the defect in periodicity and the ultrasound oscillation can be sensed by the at least one Bragg grating with an acoustic sensitivity most of which being obtained over the localized-light resonance portion.Type: ApplicationFiled: February 4, 2011Publication date: April 24, 2014Applicant: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbHInventors: Amir Rozental, Daniel Razansky, Vasilis Ntziachristos
-
Patent number: 8697854Abstract: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.Type: GrantFiled: November 24, 2009Date of Patent: April 15, 2014Assignee: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbHInventors: Dolores Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
-
Patent number: 8693618Abstract: A scanner device for computed tomography imaging of an object, includes a measurement device including a source device arranged for irradiating the object with at least one beam and a detector device arranged for detecting radiation transmitted through the object, wherein the source device has a fixed position relative the detector device, and a carrier device accommodating the object in a position between the source device and the detector device, wherein the measurement device and the carrier device are capable of a scanning movement relative to each other, and the measurement device and the carrier device have a fixed spatial orientation during the scanning movement. Furthermore, a scanning method for computed tomography imaging of an object is described.Type: GrantFiled: June 5, 2009Date of Patent: April 8, 2014Assignee: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Oleg Tischenko, Matthias Klaften, Christoph Hoeschen, Martin Hrabe de Angelis
-
Publication number: 20140093038Abstract: The invention relates to a radiation detector (10), in particular for detecting x-ray radiation, comprising a carrier substrate (11), a detector layer (12) which comprises GaN, is arranged on the carrier substrate (11) and has a thickness less than 50 ?m, and contact electrodes (13) which form ohmic contacts with the detector layer (12). The invention also relates to a measurement device which is equipped with at least one such radiation detector (10).Type: ApplicationFiled: March 2, 2012Publication date: April 3, 2014Applicant: Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GmbH)Inventors: Stefan Thalhammer, Markus Hofstetter, John Howgate, Martin Stutzman